Big pharma Bayer will spin off its plastics unit as the company moves further toward focusing solely on the life sciences market.

The plastics unit is valued at around $10 billion and Bayer’s supervisory board has unanimously approved the plans.

Bayer’s Material Science division posted sales of $14 billion last year, according to Business Insider.

The Material Science portion of the company is dedicated to producing polymers and polycarbonates.

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with Bayer

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter